Trivitron wants to set up high-end manufacturing facility in Hyderabad
Hyderabad: Medical technology company Trivitron Healthcare manufactures and distributes products in more than 170 countries. With 13 FDA and CE certified manufacturing facilities in the United States, the company invests in innovation in newborn screening, in vitro diagnostics, imaging and radiology, radiation protection, intensive care and operating room solutions. Dr GSK Velu, CMD, Trivitron Healthcare shares with Telangana today the company’s future plans and the potential they see in Telangana.
Plans for Telangana
Trivitron has invested in manufacturing in Tamil Nadu, Andhra Pradesh, and Maharashtra in the past. We are seriously considering investing in Telangana at Sultanpur Medical Devices Park (near Hyderabad). Once the Covid situation calms down, we will finalize our plans. The state has established itself as an attractive destination and the government is very proactive and there is a lot of motivation. We could consider products that will be either electronic medical equipment or those needed in the pharmaceutical and biotechnology industry, because the state has a large base for these industries.
click here for more information on Hyderabad
We have R&D and manufacturing facilities in four countries: India, Finland, Turkey and China. We have stand-alone R&D facilities in Austria and the United States. We also plan to begin manufacturing in the United States in the next quarter through an acquisition. Over the next 2-3 years, we will be investing through our internal accruals and positions that we will explore for external funding. The company employs 2,000 people worldwide, 70 to 80% of whom are in India.
We export to more than 170 countries and the main markets are the United States, Europe, the Middle East and Africa. We also export to Japan and there is significant growth here. We also see growth opportunities in Southeast Asia and Latin America. We supply both developed and developing markets. In terms of categories, in vitro diagnostics and radiology are the key segments that contribute a significant portion of our revenues.
In addition to in vitro diagnostics (newborn screening and point-of-care diagnostics) and radiology (X-rays, ultrasound, mammography and radiation protection), the third area of ââintervention concerns intensive care units with products such as ventilators, monitors and defibrillators where we will invest in manufacturing. We will also invest in the dialysis segment in the future.
Trivitron is developing different strategies for different markets. In India, we are ready to take on the biggest multinationals. We will enter CTMR (computed tomography / magnetic resonance), cath labs, advanced radiology and diagnostic products over the next 2-3 years. In overseas markets, we focus on niche markets. For example, in the United States, Europe and Japan, we are focusing on newborn screening and radiation therapy equipment.
Trivitron quickly jumped into Covid-related products by examining the critical need for Covid ventilators and test kits. In 2020, as sales of conventional products took a hit, Covid products contributed most of the revenue. In 2021, business will return to normal as the impact of Covid decreases.
Over the past five years, we have made substantial investments in R&D and manufacturing. We are in investment mode. Until 2012 we had no manufacturing revenue and after that we went from a trading company to a manufacturing run business. We also source the latest technology from the US and Europe to develop best-in-class products.
Now you can get handpicked stories from Telangana today to Telegram everyday. Click on the link to subscribe.
Click to follow the Telangana Today Facebook page and Twitter .